These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30187561)

  • 1. Positioning biologics-A case-based discussion: Anti-tumor necrosis factor biological agents/biosimilars.
    Leong RW; Katelaris PH
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():14. PubMed ID: 30187561
    [No Abstract]   [Full Text] [Related]  

  • 2. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars in inflammatory bowel disease.
    Moore GT
    Med J Aust; 2016 Oct; 205(7):294-5. PubMed ID: 27681963
    [No Abstract]   [Full Text] [Related]  

  • 4. Insights on the use of biosimilars in the treatment of inflammatory bowel disease.
    Zheng MK; Shih DQ; Chen GC
    World J Gastroenterol; 2017 Mar; 23(11):1932-1943. PubMed ID: 28373759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach.
    Peyrin-Biroulet L; Danese S; Cummings F; Atreya R; Greveson K; Pieper B; Kang T
    Expert Rev Gastroenterol Hepatol; 2019 Aug; 13(8):731-738. PubMed ID: 31322440
    [No Abstract]   [Full Text] [Related]  

  • 6. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
    Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in Inflammatory Bowel Disease.
    Buchner AM; Schneider Y; Lichtenstein GR
    Am J Gastroenterol; 2021 Jan; 116(1):45-56. PubMed ID: 33110013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
    Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
    [No Abstract]   [Full Text] [Related]  

  • 10. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease.
    Bhat S; Limdi JK; Cross RK; Farraye FA
    Dig Dis Sci; 2021 Aug; 66(8):2513-2532. PubMed ID: 34176024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know?
    Dwadasi S; Israel A; Rubin DT
    Gastrointest Endosc Clin N Am; 2019 Jul; 29(3):405-419. PubMed ID: 31078244
    [No Abstract]   [Full Text] [Related]  

  • 14. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.
    Pouillon L; Bossuyt P; Peyrin-Biroulet L
    Expert Opin Biol Ther; 2016 Oct; 16(10):1277-90. PubMed ID: 27329436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: in support of extrapolation of indications.
    Ebbers HC
    J Crohns Colitis; 2014 May; 8(5):431-5. PubMed ID: 24594005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
    Gecse KB; Cumming F; D'Haens G
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
    Buer L; Høivik ML; Medhus AW; Moum B
    Dig Dis; 2017; 35(1-2):74-82. PubMed ID: 28147370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positioning biologics-A case-based discussion: Ustekinumab.
    Begun J
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():16-17. PubMed ID: 30187551
    [No Abstract]   [Full Text] [Related]  

  • 19. Biosimilar medicines in inflammatory bowel disease.
    Moum B; Lundin KE
    Tidsskr Nor Laegeforen; 2014 Apr; 134(8):819-20. PubMed ID: 24780979
    [No Abstract]   [Full Text] [Related]  

  • 20. Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?
    Kotze PG; Danese S
    Curr Med Chem; 2019; 26(2):246-247. PubMed ID: 30907307
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.